4.2 Article

Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry

期刊

PULMONARY CIRCULATION
卷 12, 期 1, 页码 -

出版社

WILEY
DOI: 10.1002/pul2.12001

关键词

chronic thromboembolic pulmonary hypertension; pulmonary arterial hypertension; survival

资金

  1. Actelion

向作者/读者索取更多资源

Pulmonary hypertension, especially pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, is a rare and progressive condition. This retrospective analysis of the Swiss Pulmonary Hypertension Registry found that newly diagnosed patients are older, have a more balanced gender distribution, improved hemodynamics, and better survival rates.
Pulmonary hypertension (PH), especially pulmonary arterial and chronic thromboembolic pulmonary hypertension (PAH/CTEPH), are rare and progressive conditions. Despite recent advances in treatment and prognosis, PH is still associated with impaired quality of life and survival. Long-term PH-registry data provide information on the changing PH-epidemiology and may help to direct resources to patient's needs. This retrospective analysis of the Swiss Pulmonary Hypertension Registry includes patients newly diagnosed with PH (mainly PAH/CTEPH) registered from January 2001 to June 2019 at 13 Swiss hospitals. Patient characteristics (age, body mass index, gender, diagnosis), hemodynamics at baseline, treatment, days of follow-up, and events (death, transplantation, pulmonary endarterectomy, or loss to follow-up) at last visit were analyzed. Patients were stratified into four time periods according to their date of diagnosis. Survival was analyzed overall and separately for PAH/CTEPH and time periods. 1427 PH patients were included (thereof 560 PAH, 383 CTEPH). Over the years, age at baseline (mean +/- SD) significantly increased from 59 +/- 14 years in 2001-2005 to 66 +/- 14 years in 2016-2019 (p < 0.001) while the gender distribution tended toward equality. Mean pulmonary artery pressure and pulmonary vascular resistance significantly decreased over time (from 46 +/- 15 to 41 +/- 11 mmHg, respectively, 9 +/- 5 to 7 +/- 4 WU, p < 0.001). Three-year survival substantially increased over consecutive periods from 69% to 91% (for PAH 63%-95%, for CTEPH 86%-93%) and was poorer in PAH than CTEPH independently of time period (p < 0.001). Most patients were treated with mono- or combination therapy and an increasing number of CTEPH underwent pulmonary endarterectomy (40% 2016-2019 vs. 15% 2001-2005). This long-term PH registry reveals that over two decades of observation, newly diagnosed patients are older, less predominantly female, have less impaired hemodynamics and a better survival.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据